Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anlon HealthcareNSE:AHCL +2.47%17 Return-on-Tangible-Asset is 11.23% as of Mar. 2026, which is 39% above its 10-year median of 8.06. GuruFocus rates NSE:AHCL with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Anlon Healthcare ranks better than 73.78% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Anlon Healthcare's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹420 Mil. Anlon Healthcare's average total tangible assets for the quarter that ended in Mar. 2026 was ₹3,739 Mil. Therefore, Anlon Healthcare's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 11.23%.
The historical rank and industry rank for Anlon Healthcare's Return-on-Tangible-Asset or its related term are showing as below:
NSE:AHCL'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -0.13 Med: 8.06 Max: 13.27
Current: 8.66
During the past 5 years, Anlon Healthcare's highest Return-on-Tangible-Asset was 13.27%. The lowest was -0.13%. And the median was 8.06%.
NSE:AHCL's Return-on-Tangible-Asset is ranked better than 73.78% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs NSE:AHCL: 8.66
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Anlon Healthcare Return-on-Tangible-Asset Related Terms
Anlon Healthcare Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Anlon Healthcare's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:AHCL vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 11.23% mean?
Anlon Healthcare (NSE:AHCL) has a Return-on-Tangible-Asset of 11.23% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Anlon Healthcare and its competitors. This is 39% above median its historical median of 8.06. According to the industry distribution chart, Anlon Healthcare ranks #264 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 26.2%.
Is Anlon Healthcare's Return-on-Tangible-Asset too high?
Anlon Healthcare's current Return-on-Tangible-Asset of 11.23% is 39% above median its 10-year median of 8.06. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. Anlon Healthcare's value of 11.23% is 256.5% above this industry median. Based on the distribution chart, Anlon Healthcare ranks #264 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Anlon Healthcare has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #264 out of 1007 companies for Return-on-Tangible-Asset. This puts Anlon Healthcare in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.15. Anlon Healthcare's value of 11.23% is 256.5% above this benchmark. While the company's 10-year median is 8.06 vs. the industry median of 3.15, Anlon Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anlon Healthcare's current Return-on-Tangible-Asset of 11.23% is 256.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Anlon Healthcare and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anlon Healthcare's current Return-on-Tangible-Asset is 11.23%, which is 39% above median its own 10-year median of 8.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current Return-on-Tangible-Asset of 11.23%. The current Return-on-Tangible-Asset is 11.23%, which is 39% above median its 10-year median of 8.06 and 256.5% above the Drug Manufacturers industry median of 3.15. Anlon Healthcare's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current Return-on-Tangible-Asset is 11.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
17GF Score
Get the complete analysis for NSE:AHCL
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
